Investigational Site Number: 2030001

Prague 190 00

9 studies enrolling now · 27 studies all time

What they study most

Asthma, Atopic Dermatitis, Breast Cancer, Celiac Disease, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Rhinosinusitis With Nasal Polyps, Coeliac Disease, Fabry Disease, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Glycogen Storage Disease Type II (GSD-II), Glycogen Storage Disease Type II;Pompe's Disease

Studies at this site

• A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes — Recruiting now
• A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction — Recruiting now
• Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa — Recruiting now
• Pompe Pregnancy Sub-Registry — Recruiting now
• Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) — Recruiting now
• International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab — Enrolling by invitation
• Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis — Completed
• Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP — Enrolling by invitation
• Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS) — Running, not enrolling
• A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease — Running, not enrolling
• A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps — Running, not enrolling
• A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant — Running, not enrolling
• A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease — Running, not enrolling
• Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients — Completed
• A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa — Completed
• Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma — Running, not enrolling
• Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer — Stopped early
• Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis — Completed
• Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis — Completed
• First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma — Completed
• A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis — Completed
• Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients — Completed
• Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease — Completed
• A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD) — Completed
• A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients — Stopped early